201 related articles for article (PubMed ID: 21890778)
1. Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc.
Swenson LC; Mo T; Dong WW; Zhong X; Woods CK; Thielen A; Jensen MA; Knapp DJ; Chapman D; Portsmouth S; Lewis M; James I; Heera J; Valdez H; Harrigan PR
Clin Infect Dis; 2011 Oct; 53(7):732-42. PubMed ID: 21890778
[TBL] [Abstract][Full Text] [Related]
2. Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial.
McGovern RA; Thielen A; Portsmouth S; Mo T; Dong W; Woods CK; Zhong X; Brumme CJ; Chapman D; Lewis M; James I; Heera J; Valdez H; Harrigan PR
J Acquir Immune Defic Syndr; 2012 Nov; 61(3):279-86. PubMed ID: 23095934
[TBL] [Abstract][Full Text] [Related]
3. Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies.
McGovern RA; Thielen A; Mo T; Dong W; Woods CK; Chapman D; Lewis M; James I; Heera J; Valdez H; Harrigan PR
AIDS; 2010 Oct; 24(16):2517-25. PubMed ID: 20736814
[TBL] [Abstract][Full Text] [Related]
4. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.
Cooper DA; Heera J; Goodrich J; Tawadrous M; Saag M; Dejesus E; Clumeck N; Walmsley S; Ting N; Coakley E; Reeves JD; Reyes-Teran G; Westby M; Van Der Ryst E; Ive P; Mohapi L; Mingrone H; Horban A; Hackman F; Sullivan J; Mayer H
J Infect Dis; 2010 Mar; 201(6):803-13. PubMed ID: 20151839
[TBL] [Abstract][Full Text] [Related]
5. Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients.
Swenson LC; Mo T; Dong WW; Zhong X; Woods CK; Jensen MA; Thielen A; Chapman D; Lewis M; James I; Heera J; Valdez H; Harrigan PR
J Infect Dis; 2011 Jan; 203(2):237-45. PubMed ID: 21288824
[TBL] [Abstract][Full Text] [Related]
6. Maraviroc treatment in non-R5-HIV-1-infected patients results in the selection of extreme CXCR4-using variants with limited effect on the total viral setpoint.
McGovern RA; Symons J; Poon AF; Harrigan PR; van Lelyveld SF; Hoepelman AI; van Ham PM; Dong W; Wensing AM; Nijhuis M
J Antimicrob Chemother; 2013 Sep; 68(9):2007-14. PubMed ID: 23677920
[TBL] [Abstract][Full Text] [Related]
7. Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failure.
Swenson LC; Chui CK; Brumme CJ; Chan D; Woods CK; Mo T; Dong W; Chapman D; Lewis M; Demarest JF; James I; Portsmouth S; Goodrich J; Heera J; Valdez H; Harrigan PR
Antimicrob Agents Chemother; 2013 Dec; 57(12):6122-30. PubMed ID: 24080655
[TBL] [Abstract][Full Text] [Related]
8. Deep-Sequencing Analysis of the Dynamics of HIV-1 Quasiespecies in Naive Patients during a Short Exposure to Maraviroc.
Cascajero A; Rastrojo A; Díez-Fuertes F; Hernández-Novoa B; Aguado B; Moreno S; Alcami J; Pérez-Olmeda M
J Virol; 2018 Jun; 92(11):. PubMed ID: 29563289
[TBL] [Abstract][Full Text] [Related]
9. Use of cellular HIV DNA to predict virologic response to maraviroc: performance of population-based and deep sequencing.
Swenson LC; Dong WW; Mo T; Demarest J; Chapman D; Ellery S; Heera J; Valdez H; Poon AF; Harrigan PR
Clin Infect Dis; 2013 Jun; 56(11):1659-66. PubMed ID: 23429552
[TBL] [Abstract][Full Text] [Related]
10. Correlation between genotypic (V3 population sequencing) and phenotypic (Trofile ES) methods of characterizing co-receptor usage of HIV-1 from 200 treatment-naïve HIV patients screened for Study A4001078.
Portsmouth S; Valluri SR; Däumer M; Thiele B; Valdez H; Lewis M; Craig C; Thielen A; James I; Demarest J; Heera J
Antiviral Res; 2013 Jan; 97(1):60-5. PubMed ID: 23165088
[TBL] [Abstract][Full Text] [Related]
11. Evolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy.
Baroncelli S; Galluzzo CM; Weimer LE; Pirillo MF; Volpe A; Mercuri A; Cavalli A; Fragola V; Monno L; Degli Antoni A; Ladisa N; Francisci D; Bucciardini R; Floridia M
J Antimicrob Chemother; 2012 Jun; 67(6):1479-85. PubMed ID: 22361986
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.
Svicher V; Balestra E; Cento V; Sarmati L; Dori L; Vandenbroucke I; D'Arrigo R; Buonomini AR; Van Marck H; Surdo M; Saccomandi P; Mostmans W; Aerssens J; Aquaro S; Stuyver LJ; Andreoni M; Ceccherini-Silberstein F; Perno CF
Antiviral Res; 2011 Apr; 90(1):42-53. PubMed ID: 21349294
[TBL] [Abstract][Full Text] [Related]
13. Primary resistance to maraviroc in a large set of R5-V3 viral sequences from HIV-1-infected patients.
Seclén E; González Mdel M; Lapaz M; Rodríguez C; del Romero J; Aguilera A; de Mendoza C; Soriano V; Poveda E
J Antimicrob Chemother; 2010 Dec; 65(12):2502-4. PubMed ID: 20940179
[TBL] [Abstract][Full Text] [Related]
14. A genotypic test for HIV-1 tropism combining Sanger sequencing with ultradeep sequencing predicts virologic response in treatment-experienced patients.
Kagan RM; Johnson EP; Siaw M; Biswas P; Chapman DS; Su Z; Platt JL; Pesano RL
PLoS One; 2012; 7(9):e46334. PubMed ID: 23029482
[TBL] [Abstract][Full Text] [Related]
15. Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial.
Bonjoch A; Pou C; Pérez-Álvarez N; Bellido R; Casadellà M; Puig J; Noguera-Julian M; Clotet B; Negredo E; Paredes R
J Antimicrob Chemother; 2013 Jun; 68(6):1382-7. PubMed ID: 23354282
[TBL] [Abstract][Full Text] [Related]
16. Virological response to short-course maraviroc monotherapy does not predict viral tropism in HIV-1-infected treatment-naive patients.
Hernández-Novoa B; Madrid-Elena N; Dronda F; Pérez-Elias MJ; Casado JL; Pérez-Molina JA; Moreno A; Estébanez M; González J; Zamora J; Moreno S
J Antimicrob Chemother; 2014 Jul; 69(7):1916-9. PubMed ID: 24623833
[TBL] [Abstract][Full Text] [Related]
17. Improved detection of CXCR4-using HIV by V3 genotyping: application of population-based and "deep" sequencing to plasma RNA and proviral DNA.
Swenson LC; Moores A; Low AJ; Thielen A; Dong W; Woods C; Jensen MA; Wynhoven B; Chan D; Glascock C; Harrigan PR
J Acquir Immune Defic Syndr; 2010 Aug; 54(5):506-10. PubMed ID: 20512044
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcome of maraviroc-containing therapy in heavily pre-treated HIV-1-infected patients.
van Lelyveld SF; Symons J; van Ham P; Connell BJ; Nijhuis M; Wensing AM; Hoepelman AI
Int J Antimicrob Agents; 2016 Jan; 47(1):84-90. PubMed ID: 26585497
[TBL] [Abstract][Full Text] [Related]
19. 48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study.
Nozza S; Pignataro AR; Galli L; Svicher V; Alteri C; Boeri E; Ripa M; Castagna A; Sampaolo M; Clementi M; Perno CF; Lazzarin A
New Microbiol; 2016 Jul; 39(3):192-196. PubMed ID: 27704143
[TBL] [Abstract][Full Text] [Related]
20. Maraviroc: perspectives for use in antiretroviral-naive HIV-1-infected patients.
Vandekerckhove L; Verhofstede C; Vogelaers D
J Antimicrob Chemother; 2009 Jun; 63(6):1087-96. PubMed ID: 19377064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
